Coherus and Junshi Biosciences Announce FDA Approval of

–  LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy...

Related Keywords

California ,United States ,China ,Guangzhou ,Guangdong ,Massachusetts ,Shanghai ,Beijing ,Suzhou ,Jiangsu ,Maryland ,Chinese ,Junshi Bioscience ,Hill Knowlton ,Coherus Biosciences ,Jodi Sievers ,Zhi Li ,Ruihua Xu ,Judy Stecker ,Junshi Biosciences ,Denny Lanfear ,Exchange Commission ,Drug Administration ,Hospital Cancer Center ,Vp Corporate Communications ,Administration In Prescribing Information ,Shanghai Junshi Biosciences Co Ltd ,Ir Team ,Exchange Commission On ,Pr Team ,Harvard Medical School ,Surface Oncology Inc ,Neck Cancer Alliance ,Coherus Biosciences Inc ,Neck Cancer Foundation ,Nasdaq ,Sun Yat Sen University Cancer Center ,Public Affairs ,Daylight Time ,Chief Executive Officer ,Jong Chul Park ,Assistant Professor ,Neck Cancers ,Massachusetts General Hospital Cancer ,For Global ,Blinded Independent Review Committee ,Oral Head ,Neck Cancer ,Thyroid Head ,Fatal Immune Mediated Adverse ,Prescribing Information ,Mediated Nephritis ,Stevens Johnson Syndrome ,Connective Tissue ,Allogeneic Hematopoietic Stem Cell Transplant ,Private Securities Litigation Reform Act ,Surface Oncology ,Coheru Quarterly Report ,Vice President ,Nasdaq Chrs ,Nc ,Oqtorzi ,Toripalimab ,Fda Approval ,Coherus ,Nasopharyngeal Carcinoma ,